Last updated: May 24, 2026
Omeprazole (API) and sodium bicarbonate are widely sourced building blocks used across gastroenterology products, including omeprazole tablets/capsules and effervescent or buffered formulations. Supplier shortlists depend on whether the need is API, excipients, or finished-dose contract manufacturing.
What companies supply omeprazole API for branded and generic formulations?
Omeprazole is a mature proton pump inhibitor with a global API supply chain. Buyers typically qualify multiple sites under DMF (US) and/or CEP (Europe), then narrow to approved suppliers during vendor audits.
Key omeprazole API supplier types
- API manufacturers with DMFs/CEP listings for procurement by generic and branded formulators.
- Specialized API producers focused on acid-stable API crystallization, packaging, and polymorph control.
- Contract manufacturers producing omeprazole intermediates plus API finishing under quality systems suitable for US FDA submissions.
Where supply concentration tends to appear
Supply can concentrate around a small number of active DMF-holders and large-scale API plants, but secondary suppliers exist in China and India for many years of commercial continuity. For procurement, the practical risk is not “availability,” but qualification timing and site-specific compliance history.
Which suppliers make sodium bicarbonate for pharmaceutical-grade buffered products?
Sodium bicarbonate is an old excipient and gas-evolving component used in buffered, effervescent, and antacid combinations. Supply typically comes from:
- Excipients specialists (pharmaceutical grade)
- Large inorganic chemical producers supplying pharma-compliant grades
- Contract packagers and reprocessors with controlled specs, particle size, and trace impurity control
What buyers screen for in sodium bicarbonate qualification
- Particle size distribution and bulk density (impacts effervescence and dissolution)
- Sodium carbonate and chloride impurities (affects pH and taste, can impact stability)
- Micro limits and endotoxin where relevant to route of administration
What are the main supplier pathways for omeprazole + sodium bicarbonate combination products?
When omeprazole is paired with sodium bicarbonate, supply typically splits into:
- Omeprazole API sourced from an API vendor qualified for pharmaceutical use
- Sodium bicarbonate sourced as a pharmaceutical excipient grade (not industrial grade)
- Finished-dose manufacturing handled by a contract manufacturer or in-house plant using validated mixing, granulation, and compression or capsule filling processes
Typical dosage-form and manufacturing implications
- Effervescent or buffered oral dosage: requires tighter control of moisture, mixing uniformity, and carbonation-related stability.
- Delayed-release omeprazole products: require barrier coating processes and dissolution testing alignment for release specifications.
What finished-dose manufacturers produce omeprazole buffered or combination products?
Finished-dose sourcing usually sits with CDMOs that already run:
- gastro-resistant coating lines for enteric-delayed or gastro-resistant capsules/tablets
- effervescence-capable dry mixing and packaging systems
- stability programs aligned to omeprazole’s moisture/acid sensitivity constraints
In practice, buyers select CDMOs based on:
- ability to run gastro-resistant coatings at scale
- validated dissolution matching and specifications for multi-component systems
- regulatory readiness for ANDA/BLA-style documentation packages
What patents or exclusivity issues affect supply decisions for omeprazole products?
Omeprazole itself is off-patent globally, which generally increases the supplier universe. Supply chain risk is more linked to:
- site qualification and DMF/CEP status for APIs
- specific formulation IP for buffered/combination dosage forms
- whether the target product is branded, generic, or authorized generic
How do you select suppliers for omeprazole and sodium bicarbonate without supply-chain failure risk?
A procurement-grade supplier selection process usually includes:
- Verification of pharmaceutical-grade specifications at incoming QC
- Confirmation of regulatory documentation readiness (DMF/CEP for API; excipient certificates for sodium bicarbonate)
- Plant-level audit of GMP compliance history
- Analytical capability for critical quality attributes (impurity profile, polymorph control, particle size for bicarbonate)
Supplier mapping summary (procurement view)
| Need |
Typical supplier category |
Buyer deliverable for qualification |
| Omeprazole API |
API manufacturer with pharma regulatory filings |
DMF reference and site GMP documentation |
| Sodium bicarbonate |
Pharma-grade excipient supplier or inorganic producer with pharma grade |
CoA specs, impurity profile, microbiology if needed |
| Combination dosage form |
CDMO or dosage-form manufacturer |
Process validation plan, stability program, dissolution comparability |
Key Takeaways
- Omeprazole supply is broad due to maturity of the API and extensive global manufacturing capacity.
- Sodium bicarbonate supply is also broad, but pharma-grade qualification depends on impurity control and physical properties.
- For omeprazole + sodium bicarbonate combination products, the biggest procurement constraint is typically formulation execution and quality system readiness at the finished-dose manufacturer level, not raw material availability.
FAQs
1) Can sodium bicarbonate be sourced from multiple excipient suppliers for omeprazole buffered formulations?
Yes, but changes can affect effervescence performance and pH-related dissolution, so buyers qualify suppliers under established specs and run dissolution matching as part of tech transfer.
2) Do omeprazole API polymorphs matter for generic formulation performance?
Yes. Buyers typically screen for polymorph or crystallinity control because it can shift dissolution rate and impurity profiles, impacting bioequivalence and stability.
3) Are there regulatory documentation differences between sourcing omeprazole API and sodium bicarbonate excipient?
Yes. Omeprazole API sourcing is typically tied to DMF/filings and site GMP readiness, while sodium bicarbonate is commonly qualified via excipient specs and certificates of analysis backed by GMP quality systems.
4) What is the main cause of delays in switching omeprazole API suppliers?
Site qualification and change-management documentation, including analytical method alignment and regulatory file updates tied to the API source.
5) Do finished-dose manufacturers need specialized lines for omeprazole + sodium bicarbonate dosage forms?
Yes, buffered or effervescent formats often require specific mixing, moisture control, and packaging controls, plus validated gastro-resistant or delayed-release processing depending on the omeprazole dosage form.
References
- FDA. “ANDA Drug Products; Evidence/Requirements for Approval.” U.S. Food and Drug Administration.
- EMA. “Guideline on Impurities in Medical Products.” European Medicines Agency.
- FDA. “Drug Master Files (DMF).” U.S. Food and Drug Administration.
